1. Palmer K, Sharan N, Emtage P, Gauldie J, Muller WJ, Wan Y: Intratumoral administration of an adenovirus expressing a kinase dead form of ErbB-2 inhibits tumor growth. Gene Therapy. 2002, 9 (13): 898-905. 10.1038/sj.gt.3301712.
2. Sevignani C, Calin GA, Cesari R, Sarti M, Ishii H, Yendamuri S, Vecchione A, Trapasso F, Croce CM: Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines. Cancer Research. 2003, 63: 1183-1187.
3. Janat-Amsbury MM, Yockman JW, Lee M, Kern S, Furgeson DY, Bikram M, Kim SW: Combination of Local, Nonviral IL12 Gene Therapy and Systemic Paclitaxel Treatment in a Metastatic Breast Cancer Model. Molecular Therapy. 2004, 9: 829-836. 10.1016/j.ymthe.2004.03.015.
4. Nakamori M, Fu X, Rousseau R, Chen SY, Zhang X: Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Molecular Therapy. 2004, 9: 658-665. 10.1016/j.ymthe.2004.02.019.
5. Cowan KH, Moscow JA, Huang H, Zujewski JA, O'Shaughnessy J, Sorrentino B, Hines K, Carter C, Schneider E, Cusack G, Noone M, Dunbar C, Steinberg S, Wilson W, Goldspiel B, Read EJ, Leitman SF, McDonagh K, Chow C, Abati A, Chiang Y, Chang YN, Gottesman MM, Pastan I, Nienhuis A: Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA(MDR1) in metastatic breast cancer patients. Clinical Cancer Research. 1999, 5: 1619-1628.